VBL Therapeutics Discloses Data About VB-201 Novel Mechanism and Pre-Clinical Efficacy in Atherosclerosis
7/8/2013 10:12:52 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
TEL AVIV, Israel--(BUSINESS WIRE)--VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, announced today the publication of pre-clinical data for VB-201 in the journal of Atherosclerosis. The manuscript reports that VB-201 can broadly inhibit monocyte chemotaxis, with up to 90% efficacy in vitro. Molecular analysis revealed that the effect of VB-201 was not restricted to a specific chemotactic ligand or receptor. In vivo, oral treatment with VB-201 reduced monocyte migration in a peritonitis model and inhibited atheroma development in ApoE-/-mice, without affecting cholesterol or triglyceride levels.
Help employers find you! Check out all the jobs and post your resume.
comments powered by